What You Should Know:
- iSpecimen, the developer of an online marketplace that connects human biospecimen with researchers, announced that is has expanded its supplier capabilities in support of COVID-19 researchers.
- Through a new partnership with a reference lab in New York, researchers looking to validate their own COVID variant identification assays can obtain sequenced and unsequenced COVID-19 positive and negative swabs in a variety of media types through iSpecimen. This lab is
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Decentralized Clinical Trials Can Achieve Net Financial Benefits of 5X to 14X
What You Should Know:
- New data from Tufts and Medable reveal on average, decentralized clinical trials (DCTs) are associated with reduced clinical trial timelines and can achieve net financial benefits ranging from five to 14 times for Phase II and Phase III trials, respectively.
- The findings are based on financial modeling and analysis of trial data from the Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, and more than 150 clinical trials
Read More
GSK Launches Accelerated Clinical Trial with Tempus
What You Should Know:
- Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022.
- This trial’s data-driven design and site selection
Read More
Sanofi Taps BrightInsight for Development of Software as a Medical Device
What You Should Know:
- Sanofi, a global biopharmaceutical company focused on human health has inked a strategic partnership with BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solution to bring to market a next-generation digital companion application for one of Sanofi’s products.
- The BrightInsight® Platform has been selected to serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s
Read More
PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer
What You Should Know:
- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients.
- PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More
Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases
What You Should Know:
- Verily and Sosei Heptares announced a new research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform, with the goal of rapidly identifying novel drug candidates across multiple immune-based disorders.
- Together, the collaboration will focus on accelerating the development of new drug candidates against
Read More
Protai Nabs $8M for AI-Powered Drug Discovery Platform
What You Should Know:
- Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech.
- Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases.
Proteomics-based Platform for Faster and More Accurate Drug Discovery
Despite the significant
Read More
Illumina and Syapse Partner on Biomarker Testing Research Across Oncology Practices
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Illumina aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.
- Together, the two companies will work to better understand biomarker testing patterns among clinicians, which have become foundational in identifying treatment options for cancer patients. The insights gleaned from this
Read More
COVID-19: As Omicron Variant Spreads, Let’s Not Repeat Rookie Mistakes
No one should be surprised there’s another COVID variant on the loose, and yet seemingly, everyone is. The variant, named Omicron (the fifteenth letter in the Greek alphabet), was first reported to the World Health Organisation (WHO) by South Africa on November 24th. Unlike its name would suggest, Omicron is the seventh COVID-19 variant of concern—but a pandemic-fatigued global public could be forgiven for thinking it’s the twentieth.
Governments across the developed world have pushed
Read More
Quidel Corporation Acquires Ortho Clinical Diagnostics for $6B
What You Should Know:
- Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) jointly announced that they have entered into a definitive agreement in which Quidel will acquire Ortho.
- The acquisition will create a global leader in diagnostics, bringing together two highly complementary portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing.
Financial Terms of
Read More
